Mizoribine is an orally available immunosuppressive agent, which has been on the market since 1984 in Japan for the prevention of rejection in renal transplantation.
Mizoribine is an orally available immunosuppressive agent, which has been on the market since 1984 in Japan for the prevention of rejection in renal transplantation. 1) In contrast to other immunosuppressive agents (e.g., azathioprine), mizoribine has been shown in animal experiments to lack oncogenicity and has shown clinically a low incidence of severe adverse drug reactions (such as myelosuppression and hepatotoxicity), making it useful in long-term immunosuppressive therapy.
2) After oral administration, mizoribine is absorbed rapidly from the gastro-intestinal tract and distributed into living cells according to a concentration gradient between the extracellular and intracellular environment. It is completely eliminated from blood circulation within 24 h, and is excreted in urine (85%), feces (9.7%), and bile (Ͻ1%). 1, 3) As elimination rate of mizoribine is highly dependent on renal function, low-dose mizoribine (1 to 3 mg/kg/d) was administered to patients whose renal function did not return soon after transplantation. However, renal function returns much earlier following transplantation due to the concomitant use of calcineurin inhibitors. High-dose mizoribine (5 mg/kg/d) has been administered since 1998 to a number of patients, and has been shown to be safe and well tolerated in renal transplant patients at doses up to 5 mg/kg/d. 4, 5) In addition, Akiyama et al. reported that patients treated with Ն5 mg/kg/d of mizoribine showed about 20% fewer acute rejection episodes at 3 months post-transplantation than those with Ͻ5 mg/kg/d of mizoribine. 4) Recently, phase 1 single-and multiple-dose studies have been carried out to confirm the safety, tolerability, and pharmacokinetics of higher-dose (up to 12 mg/kg/d) mizoribine. 5) In the phase 1 study, no notable or clinically relevant abnormality was observed in the clinical laboratory values except for transient elevation in serum uric acid at the highest dose level (multiple dose of 12 mg/kg/d). 5) In the present study, to evaluate the pharmacokinetic characteristics of mizoribine in subjects with normal renal function, we estimated the population pharmacokinetic parameters of mizoribine using a nonlinear mixed effects model (NONMEM) program. 6) Pharmacokinetic data for population analysis were obtained in the previous phase 1 study, where 24 healthy Caucasian male subjects participated in a singledose (3, 6, 9, 12 mg/kg) study, and 12 subjects participated in a multiple-dose (6, 12 mg/kg/d) study. 5) In addition, to assess linearity and constancy in the pharmacokinetics of mizoribine, the pharmacokinetic parameters in individual 36 subjects were obtained from the population estimates according to Bayes' theorem using the NONMEM post-hoc option. 6) We further evaluated the precision of Bayesian analysis in the sparse sampling protocol by using pharmacokinetic data obtained from 24 subjects in the single-dose study.
5) MATERIALS AND METHODS
Pharmacokinetic Data Serum mizoribine concentration data for population pharmacokinetic analysis were obtained in the previous study. 5) Briefly, 36 healthy Caucasian males, aged 18-45 years old (mean: 25.8) and weighing 54.4-98.2 kg (mean 75.6), took mizoribine in the two trials. Twenty-four subjects participated in the single-dose study; and 12 subjects participated in the multiple-dose study. The single-dose study was enrolled with 4 dose levels (3, 6, 9, 12 mg/kg using 50 mg tablets) of 6 subjects. Blood samples were collected for mizoribine analysis at predose (Hour 0) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h postdose. The multiple-dose design with 2 dose levels of mizoribine was investigated in 2 groups of 6 subjects. In Dose Group 1, each subject received a once-daily administration of 6 mg/kg mizoribine on Days 1 to 5 (inclusive). Blood samples were collected for mizoribine analysis at predose (Hour 0) and at 0. Estimation of Population Pharmacokinetic Parameters of Mizoribine Population mean pharmacokinetic parameters and their interindividual variations were estimated using the NONMEM analysis, for which we used the first-order conditional estimation method in the present study.
6) The one-compartment model with first-order absorption was parameterized in terms of absorption lag time (ALAG), absorption rate constant (KA), the apparent volume of distribution (V/F), and oral clearance (CL/F) with NONMEM-PREDPP library subroutines, ADVAN2 and TRANS2.
6) The absorption lag time in the ith individual (ALAG i ) was modeled using the following equation:
where q 1 is the predicted population mean of the absorption lag time. The absorption rate constant in the ith individual (KA i ) was modeled using the following equation:
where q 2 is the predicted population mean of the absorption rate constant, and h KA i is a random variable distributed with a mean of zero and variance of w 2 KA . The apparent volume of distribution in the ith individual (V/F i ) was modeled using the following equation:
where q 3 is the predicted population mean of the apparent volume of distribution, and h V/F i is a random variable distributed with a mean of zero and variance of w 2 V/F . Oral clearance in the ith individual (CL/F i ) was modeled using the following equation:
where q 4 is the predicted population mean of oral clearance, and h CL/F i is a random variable distributed with a mean of zero and variance of w 2 CL/F . The creatinine clearance (CLcr) value (in l/h) was calculated using the Cockcroft-Gault equation as follows: (5) where AGE is age, WT is body weight, and Scr is serum creatinine concentration (in mg/dl). Finally, the jth observed serum concentration in the ith subject (C ij ) was assumed to be randomly and normally distributed from the predicted value (C* ij ):
C ij ϭC* ij ϩe ij (6) where e ij is a random variable that describes intraindividual variability with a mean of zero and variance of s 2 . Bayesian Analysis The pharmacokinetic parameters of mizoribine in individual 36 subjects were estimated according to Bayes' theorem using the NONMEM post-hoc option. 6) We examined linearity in the pharmacokinetics of mizoribine in the single-dose (3, 6, 9, 12 mg/kg) study, based on pharmacokinetic parameters in individual subjects. In addition, in order to examine constancy in the disposition of mizoribine, the pharmacokinetic parameters in the single-dose study were compared to those in the multiple-dose (6, 12 mg/kg/d) study. We further evaluated the precision of Bayesian analysis in the sparse sampling protocol by using pharmacokinetic data obtained from 24 subjects in the single-dose study. 5) That is, the mean absolute differences (MAD) for KA, CL/F, and V/F between the full and reduced sampling protocols were calculated as follows: (7) where P full(i) is the parameter estimate from the full sampling protocol consisting of 9 sampling points (0.5, 1, 2, 3, 4, 6, 8, 12, 24 h postdose) in the ith subject, and P reduced(i) is the parameter estimate from any reduced sampling protocol in the ith subject.
Statistical Analysis Values are expressed as the meanϮS.D. Comparisons between the means of multiple groups were made by using one-way analysis of variance (ANOVA). p values of less than 0.05 were considered significantly different.
RESULTS

Population Pharmacokinetic Parameters of Mizoribine
The mean and S.D. values of serum mizoribine concentration following single oral administration at doses of 3, 6, 9, or 12 mg/kg are shown in Fig. 1 . The individual observed concentrations of mizoribine following once-and twice-daily administrations at the dose of 6 mg/kg are shown in Figs. 2 and 3, respectively. The population pharmacokinetic parameters were estimated using serum mizoribine concentration data obtained from all 36 subjects. NONMEM provides estimates of the standard error (S.E.) for all parameters, and S.E. can be used to define 95% confidence intervals (CI) for true parameter values: 95% CIϭ(the estimated parameter value)Ϯ 1.96 · S.E. Table 1 shows the population pharmacokinetic parameters of mizoribine and their 95% CI estimated by NON-MEM analysis. The mean values of ALAG and KA were estimated to be 0.349 h and 0.869 h Ϫ1 , respectively, indicating that mizoribine is very rapidly absorbed after oral administration. The mean value of V/F was estimated to be 0.834 · WT l. The mean (ϮS.D.) CLcr values in 36 subjects were 7.54 (Ϯ1.40) l/h. The CL/F value was estimated to be 1.93 · CLcr l/h, which suggested that the CL/F value is greater than the renal glomerular filtration rate, and that renal tubular secretion is involved in the elimination pathway. In the present study, we did not introduce interindividual variability in ALAG for simplicity. On the other hand, the w KA , w V/F , and w CL/F values were estimated to be 0.269, 0.354, and 0.332, respectively, which indicated that the interindividual variability of KA, V/F, and CL/F was significant. In addition, Fig. 1 shows concentration-time curves calculated according to population pharmacokinetic parameters following single administration at the 4 dose levels. The predicted serum concentrations of mizoribine were well correlated with the ob- served serum concentration of the drug at any dose tested, which indicated that the pharmacokinetics can be well described by a simple one-compartment model with first-order absorption. Linearity and Constancy in the Pharmacokinetics of Mizoribine The pharmacokinetic parameters (KA, V/F, CL/F) in individual 36 subjects were obtained from population estimates according to Bayes' theorem using the NON-MEM post-hoc option. In addition, the pharmacokinetic parameters (t 1/2 , T max , C max , AUC) in each subject were calculated using the ALAG, KA, V/F, and CL/F values in individual 36 subjects. Table 2 shows the mean values of KA, weight-corrected apparent distribution volume ((V/F)/WT), CLcr-corrected oral clearance ((CL/F)/CLcr), t 1/2 , T max , C max , and AUC in each single-and multiple-dose group. Each parameter value of KA, (V/F)/WT, and (CL/F)/CLcr was not significantly different among 6 groups (p>0.05 by one-way ANOVA), which indicated that the pharmacokinetics of mizoribine was linear for dose-escalation and stationary for repetitive administration. Moreover, the mean values of t 1/2 and T max , which ranged from 2.68 to 3.08 h and from 2.28 to 2.67 h, respectively, did not change with dose escalation in the single-dose study (Table 2) . On the other hand, the mean values of calculated C max increased linearly along with dose escalation, and were 2.65, 5.32, 6.32, and 9.31 mg/ml at doses of 3, 6, 9, and 12 mg/kg, respectively. Similarly, the mean values of calculated AUC 0→∞ at the 4 dose levels in the single-dose study increased linearly as the dose increased ( Table 2) . Figures 2 and 3 show the predicted serum mizoribine concentration-time curves in typical subjects. The trough mizoribine concentration was nearly equal to zero at 24 h after the dose of 6 mg/kg (Fig. 2) , whereas 0.16-1.86 mg/ml at 12 h after the dose of 6 mg/kg (Fig. 3) . The correlation between predicted and observed serum mizoribine concentrations was fairly good in all 12 subjects. These results indicated that the pharmacokinetics of mizoribine was constant for repetitive administration, and that intestinal absorption and renal excretion were not saturated even after multiple doses at up to 12 mg/kg/d.
Sparse Sampling Designs in Bayesian Analysis
In clinical practice, the estimation of pharmacokinetic parameters from only a few measurements is useful to assess drug exposure (AUC or C max ) in individual subjects, which is possible by Bayesian analysis that takes into account prior information (population mean pharmacokinetic parameters and their interindividual variability). 8) To evaluate the performance of Bayesian analysis in sparse sampling designs, we used data from 24 subjects in the single-dose study. The MAD values of KA, CL/F, and V/F in the reduced sampling protocol are shown in Fig. 4 . The objects in the rows and columns are called stars, and the lengths of the radii of each star are MAD of KA, CL/F, and V/F. The scale of the radii is given by the legend star. Panel (A), (B), and (C) in Fig. 4 show the MAD values of these parameters estimated from 5, 4, and 3 blood samples, respectively. Expectedly, the predictive performance of Bayesian analysis in these well-designed sampling protocols was fairly good: MAD values were less than 6% in all parameters. Panels (D)-(N) show the performance of Bayesian analysis in relatively poor sampling protocols. The MAD values of KA and/or V/F in panels (D)-(N) were considerably large. In addition, the precise estimation of CL/F is important to predict the AUC value at any given dose. The MAD values of CL/F in panels (D), (H), (I), (J), and (K) were not very large compared with those in panels (E), (F), (G), (L), (M), and (N), suggesting that taking two blood samples at 2-8 h after the dose is generally useful for the precise estimation of CL/F.
DISCUSSION
Pharmacokinetic data of higher-dose mizoribine were ob- tained in the previous study, in which 24 healthy Caucasian male subjects participated in a single-dose (3, 6, 9, 12 mg/kg) study, and 12 subjects participated in a multiple-dose (6, 12 mg/kg/d) study. 5) In the present study, the population pharmacokinetic parameters of mizoribine in healthy subjects were estimated using a NONMEM program ( Table 1 ). The pharmacokinetics of mizoribine was well described by a simple one-compartment model with first-order absorption (Fig.  1) . In addition, the pharmacokinetic parameters in individual 36 subjects could be obtained from population estimates according to Bayes' theorem. The predicted serum concentrations of mizoribine were correlated fairly well with the observed serum concentrations even in the multiple-dose study (Figs. 2, 3) . Furthermore, Bayesian analysis seemed useful to estimate the precise parameters from a limited number of blood samples in individual subjects (Fig. 4) . Nucleosides and nucleoside analogs are hydrophilic mole- cules and require transporters to enter cells. 9) Recently, Patil et al. reported the presence of two Na ϩ -dependent concentrative nucleoside transporters (CNT1/N2 and CNT2/N1) on the brush border membrane in the human intestine.
10) The CNT1/N2 transporter is pyrimidine-nucleoside preferring, and thymidine serves as a model substrate. In contrast, the CNT2/N1 transporter is generally purine-nucleoside preferring, and inosine, guanosin, and formycin B serve as model substrates. Ribavirin is a broad-spectrum antiviral drug structurally related to guanosine, and is actively transported across the brush border membrane of the jejunum via the CNT2/N1 transporter with high affinity.
10) Pharmacokinetic studies of oral ribavirin in adult subjects have demonstrated a lack of proportionality in the peak plasma concentrations achieved on increasing the dose from 600 to 2400 mg, suggesting saturable absorption of the drug.
11) Since the chemical structure of mizoribine is similar to that of inosine and guanosine, mizoribine as well as ribavirin may be transported via CNT2/N1 in the intestine. 12) In the present study, however, the mean values of calculated C max increased linearly along with dose escalation (Fig. 1) . The individual KA values were nearly constant at all dose levels in the single-dose and multiple-dose studies (Table 2 ). These results suggested that the intestinal absorption of mizoribine was not saturated at 12 mg/kg/d or approximately 900 mg/d.
In the previous study, the mean percentage of urinary recovery of mizoribine was 78% following single oral administration at 12 mg/kg, suggesting that oral bioavailability (F) is high, and that most of the oral dose is excreted predominantly in urine. 5) Mizoribine is water-soluble, and plasma protein binding in human is low; therefore, it is conceivable that mizoribine is filtrated at the renal glomerulus. 13) In the present study, CL/F was modeled as a function of CLcr (Eq. 4), and the population mean CL/F value was estimated as 1.93 · CLcr (Table 1 ). This finding suggested that the renal excretion mechanisms of mizoribine were glomerular filtration and also tubular secretion, although the specific transporters in the proximal tubule of the kidney for mizoribine secretion have not been identified yet. In the present study, the mean t 1/2 and (CL/F)/WT values were almost constant in each dose group of the single-and multiple-dose studies (Table 2 ). These results suggested that the renal elimination was not saturable at any dose tested.
Target enzymes of mizoribine are inosine 5Ј-monophosphate dehydrogenase and guanosine-monophosphate synthetase. 12) Mizoribine was originally isolated as a substance having weak antimicrobial activity against Candida albicans, and was subsequently found to inhibit both humoral and cellular immunity by selectively inhibiting the proliferation of lymphocytes via the inhibition of de novo purine biosynthesis.
14) The drug has been used for the prevention of rejection in renal transplantation and also for the treatment of lupus nephritis, rheumatoid arthritis, and nephrotic syndrome. 1, 15, 16) However, the relationship between the therapeutic effect and serum concentration of mizoribine is unclear, and the optimal dose of the drug for autoimmune diseases as well as organ transplantation is still unkown. 15) Because the serum mizoribine concentration can be easily measured by an HPLC method, monitoring the serum mizoribine concentration in the patients may be useful to assess the relationship between the drug exposure (AUC and/or C max ) and response. 7, 17, 18) The present finding that the pharmacokinetic parameters in each subject could be obtained from the limited number of serum mizoribine concentration data (Fig. 4) may be valuable for the future clinical pharmacodynamic research.
In conclusion, to evaluate the pharmacokinetic characteristics of mizoribine in subjects with normal renal function, we estimated the population pharmacokinetic parameters of mizoribine using a NONMEM program. The mean values of ALAG, KA, V/F, and CL/F were estimated to be 0.349 h, 0.869 h Ϫ1 , 0.834 l/kg, and 1.93 · CLcr l/h, respectively, which indicated that orally administered mizoribine is rapidly absorbed from the intestine, distributed into the tissue, and excreted in urine via glomerular filtration and tubular secretion. In addition, Bayesian analysis, which utilizes population pharmacokinetic parameters as prior information, might be useful to assess drug exposure in individual subjects. These findings may provide new information concerning immunosuppressive therapy with higher-dose mizoribine.
